.Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX22_Selpercatinib.Selpercatinib .Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX22_Selpercatinib.Selpercatinib| name: | Selpercatinib | |
| ATC code: | L01EX22 | |
| route: | oral | |
| compartments: | 2 | |
| dosage: | 160 | mg |
| volume of distribution: | 423 | L |
| clearance: | 11.6 | L/h |
| other parameters in model implementation | ||
Selpercatinib is a selective RET kinase inhibitor approved for the treatment of patients with RET fusion-positive non-small cell lung cancer (NSCLC), and RET-mutant medullary thyroid cancer (MTC), among other RET-altered tumors. It is an orally administered, targeted therapy with demonstrated efficacy in RET-driven malignancies and is currently approved for use in multiple countries.
Population pharmacokinetics of selpercatinib in adult cancer patients across multiple Phase 1/2 studies. Parameters are based on healthy adult patients with cancer, oral administration, dosing at steady-state.
Liu, D, & van der Walt, JS (2025). Population Pharmacokinetics Modeling of Selpercatinib to Support Posology in Pediatric Patients With RET-Altered Metastatic Thyroid Cancer or Solid Tumors. CPT: pharmacometrics & systems pharmacology None –. DOI:10.1002/psp4.70042 PUBMED:https://pubmed.ncbi.nlm.nih.gov/40358020